Abstract: This study aimed to compare Korean smokers’ smoking-related biomarker levels by tobacco product type, including heat-not-burn cigarettes (HNBC), liquid e-cigarettes (EC), and traditional cigarettes (TC). Nicotine dependence levels were evaluated in Korean adult study participants including TC-, EC-, HNBC-only users and nonsmokers (n = 1586) from March 2019 to July 2019 in Seoul and Cheonan/Asan South Korea using the Fagerström Test Score. Additionally, urine samples (n = 832) were collected for the measurement of urinary nicotine, cotinine, OH-cotinine, NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol), CYMA (N-acetyl-S-(2-cyanoethyl)-L-cysteine), or CEMA (2-cyanoethymercapturic acid) using LC–MS/MS. The median (interquartile range) nicotine dependence level was not different among the three types of smokers, being 3.0 (2.0–5.0) for TC- (n = 726), 3.0 (1.0–4.0) for EC- (n = 316), and 3.0 (2.0–4.0) for HNBC- (n = 377) only users. HNBC-only users presented similar biomarker levels compared to TC-only users, except for NNAL (HNBC: 14.5 (4.0–58.8) µg/mL, TC: 32.0 (4.0–69.6) µg/mL; p = 0.0106) and CEMA (HNBC: 60.4 (10.0–232.0) ng/mL, TC: 166.1 (25.3–532.1) ng/mL; p = 0.0007). TC and HNBC users showed increased urinary cotinine levels as early as the time after the first smoke of the day. EC users’ biomarker levels were possibly lower than TC or HNBC users’ but higher than those of non-smokers.

Keywords: nicotine dependence; biomarker; smoking; electronic cigarette; heat-not-burn cigarette

1. Introduction

Cigarette smoking remains a major health concern worldwide. Up to 80–90% of lung cancers are attributable to smoking, which is also causally linked to oral, esophageal pharyngeal, renal, and cervical cancers, stroke, coronary heart diseases, and various chronic conditions [1–3]. In South Korea, approximately 37% of Korean adult males and 5.2% of Korean adult females were found to be smokers in 2017 [4].

Recently, various electronic nicotine delivery systems (ENDS), including liquid e-cigarettes (EC) and heat-not-burn cigarettes (HNBC), have been widely used as alternatives to traditional cigarettes (TC). HNBC, which is a type of cigarette heated with an electric blade at 350 °C, gives the smoker the true taste of tobacco, with reduced smoke and smell. The preference of smokers has been shifting from TC to EC and HNBC. This change in smoking patterns raises major issues such as the biochemical harmfulness of ENDS to humans, as warned by global health organizations, including the CDC and the World
Health Organization (WHO) [5,6]. Since the introduction of IQOS, a type of HNBC, in South Korea in June 2017, such HNBCs have gained popularity, accounting for 10.5% of all total tobacco sales in 2019 [7,8], and were advertised as a product with reduced harm [9]. However, the Korean Ministry of Food and Drug Safety claimed that they may not be as safe as the companies claim [10]. In Korea, according to the third smoker panel follow-up survey based on the Korea National Health and Nutrition Examination Survey (KNHANES 2017), the rate of EC usage reached a peak after the increase in cigarette prices in 2015 but decreased slightly in 2016 [11].

HNBC, EC, and TC mostly contain nicotine and other chemicals, which are inhaled through the mouth [12]. Among daily smokers, smoking patterns tend to maintain relatively stable levels of nicotine in the body, which leads to frequent smoking [13]. Intermittent smokers (ITS) or non-daily smokers also show some evidence of nicotine dependence and difficulty in smoking cessation, thus making them suffer from the adverse effects of smoking [14–16]. In fact, nicotine dependence is the determinant of cigarette smoking, because individuals smoke frequently to maintain nicotine levels, thus reducing the possibility of quitting [17].

According to the WHO, the efficacy of EC for quitting smoking has not been systematically evaluated. The basis for the effectiveness of EC for quitting smoking is extremely limited, and conclusions cannot be reached [18]. In a randomized control study conducted in New Zealand in 2013, the 6-month smoking cessation rate for groups using nicotine-containing EC and nicotine patches was 7.3% and 5.8%, respectively, but this difference was not statistically significant. Due to criticisms of the research design, there are still debates over the anti-smoking effects of EC [19]. According to the 2016 Cochran Review, EC, containing nicotine, was associated with a higher smoking rate than EC without nicotine. However, more research is needed on whether EC is superior to other supplements such as nicotine patches [20].

Nicotine dependence complexity has been reported, and multiple instruments have been adopted to evaluate the extent of nicotine dependence [21–23]. The Fagerström Test for Nicotine Dependence, which is a standard tool designed for evaluating physical addiction to nicotine, includes questions regarding the time of the first cigarette, the number of cigarettes smoked per day, the difficulty to refrain from smoking, the type of cigarette for which someone would find it difficult to give up on, and the daily smoking frequency [24,25].

One of the effective methods for measuring smokers’ exposure to cigarettes is measuring biomarker levels, which estimates the integrated exposure over a period of time [26,27]. Biomarkers also play an important role when reviewing the potential health risks of tobacco products as well as for evaluating and identifying potential product standards of components in tobacco products [28,29]. Reliable and accurate measurements of tobacco products in human biospecimen are necessary to identify and confirm tobacco use patterns and to assess their potential biological effects in the human population [30]. Exposure to nicotine, cotinine, NNAL, and alkaloids is related to the exposure to nicotine or toxicants present in cigarettes and other tobacco products [31].

Considering the possibility of the increasing interest in new tobacco products, there is a need to lay the foundation for health policy development by identifying user behaviors by cigarette type and surveying exposure levels. Considering the international cigarette consumption rate by cigarette type—TC, EC, and HNBC—comparison of the levels of smoking-specific biomarkers depending on cigarette type or addiction level can be essential to evaluate the relationship between tobacco smoking habits and potential health outcomes. However, study outcomes that contain such information are highly limited. The purpose of this study was to compare Korean smokers’ biomarker levels by type of tobacco product consumed, i.e., HNBC, EC, or TC.
2. Materials and Methods

2.1. Study Participants and Design

Under a cross-sectional design, the THINK (Tobacco and Health IN Korea) study comprising 3004 adult study participants, aged 19 years or older, including non-smokers and single, dual, or triple users of cigarettes, EC, and cigarette-type EC, were recruited using a convenience sampling method from March to June 2019 (Figure 1). In this study, we excluded participants under 19 or over 65 years of age. Pregnant women, nicotine supplement users, and patients with severe lung disease were also excluded from the selection process. Research subjects (adult male and female smokers) who voluntarily applied through public information advertisements or handouts were randomly selected from hospital outpatient centers or public places, train stations, markets, etc. To analyze urinary biomarkers, urine samples were collected from those (n = 832) who agreed to provide their urine.

![Figure 1. Study framework for smoking behavior including nicotine dependence level and biomarker levels among study participants (among nonsmokers or single-type cigarette users, those who provided a completed questionnaire and urine samples were 63 for NS and 403, 24, and 76 for TC, EC, and HNBC, respectively.).](image)

2.2. Questionnaire Development for Investigating the Tobacco Usage Behavior

To conduct the THINK study, we developed a questionnaire asking smokers’ smoking behavior based on the US PATH study questionnaire [32], KNHANES smoker panel third follow-up 2018 [11], and International Tobacco Control survey [33]. Using screening questionnaires, before conducting the main survey, smokers were classified into eight types according to the combination of tobacco products they used, that is, non-smokers/past smokers; TC-, EC-, HNBC-only users; TC–EC dual users; TC–HNBC dual users; EC–HNBC dual users; TC–EC–HNBC triple users. Questionnaires contained questions about the lifetime smoking period, cigarette brand, daily smoking amount (unit of pack was used for TC and HNBC users, and unit of puff per usage and frequency of usage were used for EC for its estimation), Fagerström dependence level, and intention to quit smoking. This study used pictures of tobacco products to reduce classification errors or confusion about the types of new cigarettes. In addition, tobacco product users (TC, EC, and HNBC) were further defined as follows:

- **Current User**: In case of responding: “I use cigarettes every day or sometimes”
- **Past Users**: In the case of responding: “I used it in the past, but not currently” and
- **Non-user**: No experience of smoking at all.
At the baseline, we excluded the users of these three products involved in various smoking cessation service programs (visiting smoking cessation clinics, using smoking cessation consultation calls, etc.).

Our survey was conducted using an online survey method (CAWI: computer-aided web intervention) and the help of trained agents of Gallop-Korea, field managers of the Integrated Research Center of Soonchunhyang University, or trained field managers in hospital-based health examination centers (Seoul National University Hospital Healthcare System Gangnam Center; Seoul National University Hospital in Bundang; Soonchunhyang University Hospital in Cheonan; Dankook University Hospital in Cheonan, South Korea). The original study procedures relating to human participants and informed consent were approved by the research ethics committee of Soonchunhyang University (IRB No. 2018-BR-046-03), and written consent was obtained.

2.3. Component of the Survey Questionnaires

The survey of the 3004 participants (smokers or non-smokers living with smokers) included questions about age, gender, education, smoking habits (smoking period, smoking volume, nicotine dependence, intention to quit smoking, smoking place, dual use status, and products used). Detailed questions about smoking/non-smoking, smoking habits, and nicotine addiction levels were also included.

Nicotine dependence was measured using the Fagerström score. The Fagerström score was divided into low dependence for a score of 1 to 2 points, upper low dependence for a score of 3 to 4 points, medium dependence for a score of 5 to 7 points, and high dependence for a score of 8 points or more by using the answers for the questions about the waiting time to the first smoke after waking up, controlling the desire to smoke, daily smoking rate, etc.

Because the daily smoking amount could not be calculated for EC users using the parameter “number of cigarette,” unlike for TC or HNBC users, we converted the number of liquid inhalations to estimate the smoking volume and calculated the Fagerström nicotine dependence score according to ISO3308:2012(E): 10 inhalations of liquid = 1 cigarette).

Questions about the experience of exposure to secondhand smoke were also included. Among the eight types of smokers who provided biospecimens (n = 832), for those who agreed, a topography assessment using CReSS was conducted. A reward card ($100) was given to research subjects who provided biospecimens and conducted the topography test.

2.4. Measurement of Biomarkers

2.4.1. Selection of Biomarkers

In this study, six types of smoking-related biomarkers were analyzed: urine nicotine, cotinine, OH-cotinine, NNAL (metabolite of NNK), CYMA and CEMA (metabolites of volatile organic compounds that is, acrylonitrile and acrolein). These biomarkers were recently selected as major smoking-related substances [34].

2.4.2. Analysis of Biomarkers

Biomarkers were analyzed using liquid chromatography and tandem mass spectrometry (LC–MS/MS) [30,35,36]. During our sample preparation period, 0.1 mL of urine was diluted 10 times with an acetonitrile and water (50:50 v/v) mixture for cotinine and OH-cotinine, nicotine, NNAL, CEMA, and CYMA analyses. The water blank was replaced with 0.1 mL of HPLC-grade water instead of urine. Then, 100 µL of the internal standard mixture (10 µg/mL) was added, and the samples were centrifuged at 5 °C for 30 min at 3600 rpm.

After centrifugation, urine samples were passed through a filter of 0.2 µm as pore size, and the supernatant solution was put into a vial; 20 µL was injected into the LC–MS/MS. For the separation of cotinine, OH-cotinine, and NNAL, the Waters Acuity 1.8 µm column was used. Low concentrations of NNAL were selected and analyzed by liquid–liquid extraction.
Our selective analysis was based on the following: cotinine: 177.1; Cotinine-d3: 180.1; OH-cotinine: 192.6; OH-cotinine-d3: 196.1; NNAL: 210.0; d3-NNAL: 213.0 m/z; CEMA: 236.0; and 13C3-CEMA: 239.0 m/z; CYMA: 217.0; and d3-CYMA: 220.0 were used as precursors. Cotinine: 80.1; Cotinine-d3: 80.0; OH-cotinine: 80.0; OH-cotinine-d3: 80.0; NNAL: 92.9; d3-NNAL: 93.0 m/z; CEMA: 105.0; 13C3-CEMA: 105.0; CYMA: 158.0; d3-CYMA: 176.0 m/z were used as products.

The detection limits in this study were as follows: 0.15 ng/mL (cotinine, OH-cotinine, nicotine), 0.5 ng/mL (CYMA, CEMA), and 1.0 pg/mL (NNAL). In this study, the quantitation limit was selected as 0.3 ng/mL (cotinine, OH-cotinine, nicotine), 1.0 ng/mL (CYMA, CEMA), and 4.0 pg/mL (NNAL).

2.4.3. Urine Sample Collection

Spot urine samples were collected from volunteers who provided answers to the survey questionnaire and agreed to provide urine. Urine samples were collected at the hospital’s examination center, Soonchunhyang Cheonan hospital smoking cessation support center, and Soonchunhyang University’s risk assessment center and Seoul metro station. We collected 30 mL or as much urine as provided in a conical centrifuge tube (50 mL). The field coordinators stored the sample tubes in an ice box and kept it until it arrived at Soonchunhyang University’s analytical lab. After checking study volunteers’ IDs, samples were delivered to the laboratory and put in a freezer at (−20 °C) until the analysis. Field inspectors were responsible for accurate labeling, sampling, and storage on cards, envelopes, and tubes, re-checking labeling and transporting to the risk assessment center at Soonchunhyang University for analysis. All analytical procedures were conducted by blind testing in accordance with the internal quality control protocol of the risk assessment institute of Soonchunhyang University.

2.5. Data Analysis

Descriptive statistics (frequencies, percentages, means, medians, and interquartile ranges) were used to describe the study population and smoking behaviors. Differences in demographics and smoking-related characteristics by sex were determined using Fisher’s exact test and the Mann–Whitney U test (Wilcoxon rank-sum test). Statistical significance was defined as a p value < 0.05.

A log-transformed linear regression analysis of outcome variables was conducted to account for the right-skewed distribution. The regression coefficients were back-transformed to estimate the geometric mean ratios when comparing different levels of the independent variable. Additionally, we conducted a sensitivity analysis among a subset of the population with low puff counts. As we observed, there were no substantial differences in the findings; the full population is reported herein. Variables that were significant (or borderline significant) in the univariate models were included in the multivariate regression model. All analyses were conducted in SAS version 9.1 (SAS Institute, Cary, NC, USA).

3. Study Results
3.1. Demographic Characteristics of the Study Subjects

The demographic characteristics of a total of 1586 study participants are summarized in Table 1. For each cigarette type, male participants were the majority, and more than about 70% were those aged 30 or older. Most of our study participants were university graduates. The proportion of participants with a high income level ($5000/month) was larger among new-type cigarette-only users (EC: 54%; HNBC: 58.4%) compared to traditional cigarette users (TC: 46%).
| Nonsmokers | TC Only | EC Only | HNBC Only |
|-----------|---------|---------|-----------|
|           | $n=167$ | $n=726$ | $n=316$   | $n=377$   |
| **Gender** |         |         |           |           |
| Male      | 56      | 621     | 229       | 300       |
| Female    | 111     | 105     | 87        | 77        |
| **Age group (Years)** |         |         |           |           |
| <29       | 37      | 182     | 91        | 35        |
| 30–39     | 60      | 135     | 108       | 106       |
| 40–49     | 41      | 176     | 73        | 147       |
| 50–59     | 20      | 159     | 42        | 85        |
| 60–69     | 7       | 65      | 2        | 3         |
| 70 or older | 2     | 12      | 9         | 1         |
| **Education** |         |         |           |           |
| Univ      | 146     | 523     | 251       | 336       |
| High school | 21    | 203     | 65        | 41        |
| **House income (M, Won)** |         |         |           |           |
| <5+       | 93      | 336     | 170       | 220       |
| 4.99 or less | 74   | 390     | 146       | 157       |
| **Marriage status** |         |         |           |           |
| Married   | 102     | 378     | 150       | 261       |
| Others    | 65      | 348     | 166       | 116       |
| **Fagerstrom score** |         |         |           |           |
| 1         | NA      | NA      | 284       | 140       |
| 2         | NA      | NA      | 224       | 144       |
| 3         | 191     | 389     | 166       | 116       |
| 4         | 36      | 47.9    | 58        | 58        |
| **Cigarettes per day** |         |         |           |           |
| <6        | NA      | NA      | 135       | 83        |
| 6–10      | 210     | 289     | 48        | 125       |
| 11–15     | 167     | 23.0    | 25        | 91        |
| 16–20     | 162     | 22.3    | 20        | 62        |
| 21–25     | 19      | 2.6     | 7         | 8         |
| 26–30     | 24      | 3.3     | 8         | 5         |
| 31+       | 9       | 1.3     | 27        | 3         |

As shown in Table 1, the proportion of the number of cigarettes smoked per day differed within smoking groups ($p < 0.05$). According to the Fagerström index, 4% or 2% of TC or HNBC smokers, respectively, were considered to be highly nicotine-dependent (score $\geq 4$).

### 3.2. Comparing the Concentration Levels of Biomarkers by Tobacco Product Type

Among those who provided urine samples, the concentration of biomarkers by single cigarette-type users was as follows: for liquid-type EC-only users, the levels of NNAL (8.3 pg/L), cotinine (322 ng/mL), and CEMA (12 ng/mL) were significantly lower than those of regular TC-only users (32 pg/mL, 730 ng/mL, and 166 ng/mL, respectively) (Table 2).

We observed that the concentrations of biomarkers for HNBC-only users were not statistically different, except for NNAL ($p = 0.0106$) and CEMA ($p = 0.0007$), compared to those for TC-only users. HNBC-only users’ NNAL and CEMA concentrations were 14.5 pg/mL and 60.5 ng/mL, respectively, and were statistically lower than the levels found in TC users (32 pg/mL, 166 ng/mL, respectively). Regardless of the cigarette type, the biomarker levels of single users were statistically different from the levels of non-smokers.

In the case of TC and EC or TC and HNBC dual users, the biomarker levels were similar to those of TC-only users. In this study, we did not include further interpretation of the level of biomarkers of EC and HNBC dual users due to their small sample size ($n = 6$).

### 3.3. Relationship between Nicotine Addiction Level and Cotinine

In this study, the nicotine addiction level was evaluated using cotinine, one of the most common smoking-related biomarkers. The table below shows the concentration of cotinine by the level of waiting time to the first smoke after waking up (31 min or more, 6–30 min, 5 min or less).

As shown in Table 3, we found that in most cases, except for EC-only users, the shorter the waiting time to the first smoke after waking up (within 5 min, 6–30 min, 31 min or more), the higher the concentrations of cotinine observed. In the case of the EC-only users, the median value of urinary cotinine was not different between those who smoked their first cigarette within 5 min after waking up and those who smoked within 6–30 min after waking up.
waking up. Due to the relatively small number of samples, we did not conduct further interpretation on this.

Table 2. Comparison between tobacco product type and biomarker concentration levels among subjects.

| (Unit: ng/mL, Except NNL: pg/mL) | Nonsmokers or Single Users | Median | P25  | P75  |
|----------------------------------|-----------------------------|--------|------|------|
| Non-smokers (n = 63)             | NNL                         | 4.9    | 4.9  | 4.9  |
|                                  | CYMA                        | 0.4    | 0.4  | 304.7|
|                                  | COT                         | 0.9    | 0.9  | 0.9  |
|                                  | OHCOT                       | 2.6    | 2.6  | 2.6  |
|                                  | NIC                         | 3.9    | 3.9  | 149.5|
|                                  | CEMA                        | 17.5   | 10.0 | 95.6 |
| TC only (n = 403)                | NNL                         | 32.0   | 4.9  | 69.8 |
|                                  | CYMA                        | 179.9  | 0.4  | 592.4|
|                                  | COT                         | 729.5  | 185.8| 1342.6|
|                                  | OHCOT                       | 2227.1 | 500.3| 4802.3|
|                                  | NIC                         | 1121.1 | 42.3 | 4558.7|
|                                  | CEMA                        | 166.1  | 25.3 | 532.1|
| EC only (n = 24)                 | NNL                         | 8.3    | 4.9  | 25.4 |
|                                  | CYMA                        | 0.4    | 0.4  | 257.3|
|                                  | COT                         | 322.2  | 0.9  | 722.8|
|                                  | OHCOT                       | 820.3  | 172.1| 2714.2|
|                                  | NIC                         | 339.1  | 3.9  | 4473.6|
|                                  | CEMA                        | 11.9   | 10.0 | 92.7 |
| HNBC only (n = 76)               | NNL                         | 14.5   | 4.9  | 58.8 |
|                                  | CYMA                        | 206.2  | 0.4  | 526.2|
|                                  | COT                         | 765.5  | 305.9| 1511.3|
|                                  | OHCOT                       | 2824.7 | 848.0| 7108.8|
|                                  | NIC                         | 874.5  | 51.4 | 7446.3|
|                                  | CEMA                        | 60.4   | 10.0 | 232.0|

Note: Detection limit: 0.15 ng/mL (cotinine, OH-cotinine, nicotine), 0.5 ng/mL (CYMA, CEMA), 1.0 ng/mL (NNL). Results were included for those who both completed the questionnaire and provided urine samples (Nonsmokers: 63, TC-only smokers: 403, EC-only smokers: 24, HNBC-only smokers: 76). p-values from Wilcoxon rank-sum test (TC vs. HNBC) were 0.0106, 0.6436, 0.4517, 0.0919, 0.7734 and 0.0007; The values between TC and EC were 0.0048, 0.0524, 0.0168, 0.0858, 0.3199 and 0.0004 for NNL, CYMA, Cotinine, OH-cotinine, Nicotine and CEMA, respectively.

Table 3. Median and interquartile ranges of urinary cotinine level by waiting time to the first smoking after wake-up.

| Waiting Time to First Smoking after Wake-Up (minutes) | Cotinine (ng/mL) |
|---------------------------------------------------|------------------|
|                                                   | N * | Median | P25  | P75  |
| **TC**                                            |     |        |      |      |
| 31+                                               | 191 | 360.0  | 0.9  | 981.8|
| 6–30                                              | 122 | 861.5  | 362.2| 1523.5|
| –5                                                | 87  | 1271.5 | 707.2| 1834.0|
| **EC**                                            |     |        |      |      |
| 31+                                               | 16  | 16.8   | 0.9  | 458.5|
| 6–30                                              | 5   | 755.7  | 425.4| 1866.7|
| –5                                                | 3   | 632.8  | 298.2| 724.8 |
| **HNB**                                           |     |        |      |      |
| 31+                                               | 44  | 614.4  | 326.4| 1305.6|
| 6–30                                              | 23  | 844.2  | 405.3| 1394.3|
| –5                                                | 8   | 1873.4 | 227.0| 3239.8|

* Excluding those who did not respond to the questionnaire or who did not agree with the CO measurement.

Similarly, using the Fagerström nicotine addiction index, the association between the addiction levels and the urinary cotinine levels was investigated (Table 4). Since it is difficult to define the number of cigarettes smoked by EC users, as defined in the ISO
smoking test, we defined 10 inhalations as one cigarette [37]. Using a survey-based daily inhalation frequency and the definition above, we calculated the total smoking amount per day.

Table 4. Frequency of cigarette smoking evaluated by the Fagerström test for nicotine dependence.

| Fagerström Index * | Cotinine |
|-------------------|----------|
|                   | N **     | Median | P25  | P75  |
| TC                | 1        | 149    | 256.9| 0.9  | 778.2|
|                   | 2        | 113    | 932.9| 448.7| 1562.2|
|                   | 3        | 119    | 985.9| 439.1| 1638.3|
|                   | 4        | 18     | 1195.1| 527.0| 1831.8|
| EC                | 1        | 11     | 0.9  | 0.9  | 32.8 |
|                   | 2        | 9      | 573.2| 310.6| 1866.7|
|                   | 3        | 3      | 724.8| 632.8| 755.7|
|                   | 4        | 0      |      |      |      |
| HNB               | 1        | 33     | 438.1| 91.1 | 861.3|
|                   | 2        | 25     | 778.6| 350.9| 1798.3|
|                   | 3        | 14     | 1491.1| 844.2| 2299.8|
|                   | 4        | 3      | 1679.5| 998.6| 3067.5|

* Fagerström Index: 1, low dependence; 2, low medium dependence; 3, medium dependence; 4 high dependence.
** Excluding those who did not respond to the questionnaire or who did not agree with CO measurement.

In the case of TC-only and HNBC-only users, we observed that urinary cotinine levels increased as the Fagerström index score increased. In the case of EC-only users, the number of samples was small; therefore, it is judged that additional interpretation is meaningless. Since dual users were not asked questions for deriving the Fagerström index, we did not include these results.

3.4. Relationship between Cigarette Smoke Intake and Nicotine Addiction Levels Adjusted for Urinary Cotinine Level

Using the levels of biomarkers among single-type cigarette smokers, we estimated the association of urinary biomarker levels with the daily cigarette smoking amount (Supplementary Tables S1 and S2). As expected, we found that there was a dose–response relationship between urinary cotinine levels and daily smoking amounts (6–10 cigarettes followed by 11–15 cigarettes, compared to 5 or less cigarettes), among TC (p < 0.05) or HNBC (p < 0.05) users after adjusting for age and sex. We found a similar dose–response relationship among EC users, but it was not statistically significant.

We further analyzed our data to evaluate the association of daily smoking amount and Fagerström nicotine addiction determinant factors, adjusted for age, sex, and urinary cotinine levels (Table 5). According to our study results, smokers who smoke their first cigarette within less than 5 min after waking up presented the largest daily smoking amount. Other Fagerström addiction determinant variables showed slightly different results depending on the cigarette type. Urinary cotinine levels were positively associated with the daily smoking amount after adjusting for the Fagerström nicotine addiction determinant factors, age, and sex.
Table 5. Association between daily smoking amount and nicotine addiction levels adjusted for age sex and urinary cotinine level.

|                           | TC (AIC = 2175) | EC (AIC = 330) | HNB (AIC = 403) |
|---------------------------|-----------------|----------------|-----------------|
|                           | B               | p-Value        | B               | p-Value        | B               | p-Value        |
| Time to first cigarette (Ref: 61+ min) |                 |                 |                 |                 |                 |                 |
| –5                        | 0.254           | <0.0001        | 1.675           | <0.0001        | 0.192           | 0.095          |
| 6–30                      | 0.180           | <0.0001        | –1.888          | <0.0001        | 0.059           | 0.466          |
| 31–60                     | 0               | 0              | 0               |                 |                 |                 |
| Difficulty to not smoke (Ref: No) |                 |                 |                 |                 |                 |                 |
| Yes                       | 0.094           | 0.0064         | –7.395          | <0.0001        | 0.030           | 0.749          |
| Type of cigarette most like (Ref: others) |                 |                 |                 |                 |                 |                 |
| Morning                   | –0.020          | 0.5331         | –4.896          | <0.0001        | 0.048           | 0.589          |
| More smoking in morning (Ref: No) |                 |                 |                 |                 |                 |                 |
| Yes                       | 0.008           | 0.8282         | 3.846           | <0.0001        | 0.194           | 0.021          |
| Smoking when sick (Ref: No) |                 |                 |                 |                 |                 |                 |
| Yes                       | 0.146           | <0.0001        | –0.093          | 0.571          | 0.156           | 0.061          |
| Gender (Ref: Female)      |                 |                 |                 |                 |                 |                 |
| Male                      | 0.296           | <0.0001        | NA              | NA             | –0.128          | 0.354          |
| Age group (Ref: 50 + years) |                 |                 |                 |                 |                 |                 |
| –29                       | –0.197          | <0.0001        | 1.842           | <0.0001        | –0.148          | 0.162          |
| 30–49                     | –0.041          | 0.2353         | –0.545          | 0.052          | –0.04           | 0.586          |
| Cotinine (ng/mL centered by median) | 0.005           | 0.0004         | 0.125           | <0.0001        | 0.006           | 0.042          |

4. Discussion

4.1. Biomarkers Levels by Cigarette Type

In this study, we found that the median values of urinary cotinine, OH-cotinine, and nicotine among TC-users were 730, 2227, and 1121 ng/mL, respectively, and the median values of CYMA and CEMA were 180 and 166 ng/m, respectively. The median concentration of NNAL was 32 pg/mL.

The concentrations of biomarkers (cotinine, OH-cotinine, nicotine, etc.) for HNBC-only users were at statistically similar levels as those of TC-only users. These results conform with those of another study that determined the concentrations of all TSNAs (including NNAL) and CEMA among HNBC users [34].

In the case of EC-only users, all biomarker levels were lower. The findings of our study are in accordance with a cross-sectional observational study conducted in the U.S. finding lower concentrations of total NNAL, CEMA, and other biomarkers among EC users [38].

4.2. Association of Biomarker Levels with Nicotine Dependence Levels

In this study, among TC users and HNBC-only users, a statistically positive association between addiction level and daily smoking amount was observed, where the higher the level of nicotine dependence, the shorter the time of the first smoke after waking up (within 5 min, 6–30 min). Various studies have found an association between higher cotinine levels and a shorter time to smoking cigarettes after waking, which might mainly be due in part to more intense smoking in response to overnight abstinence and can predict cancer [39,40].

For TC users, the concentration of urinary cotinine was significantly influenced by the first cigarette smoked after waking up, according to the evaluation scales of Fagerström nicotine dependence, adjusting for age, gender, and household income levels. Cotinine concentrations in groups that smoke within 5 min and those that smoke within 6–30 min...
showed dose–response relationships ($p < 0.05$) (Table 5). HNBC also showed a positive dose–response relationship, but it was not statistically significant.

In the case of TC- or HNBC-only users, the association with daily smoking amount was found to increase with the urinary cotinine concentration as the amount of smoking increased, compared to that in the group that smoked less than 5 cigarettes per day, and this association was statistically significant. For all three types of tobacco users, the higher the concentration of cotinine in the urine, the higher the daily smoking volume, and this association was shown to be statistically significant.

However, due to the relatively small sample size of EC users, the comparison of biomarker levels among EC users was limited, and the interpretation of the results of the EC users should be conducted with care. Differently from TC or HNBC, we considered that 10 puffs of the liquid was equal to one cigarette. It is necessary to conduct further analysis in the future to validate our findings from EC users.

Smoking cessation treatment requires an accurate understanding of the dependence on nicotine [41]. The levels of nicotine, cotinine, or NNAL (a tobacco-specific carcinogen) in biospecimens act as an indicator of the amount of tobacco smoked [42] and is one of the best indicators of potential health effects. The period to smoking the first cigarette after waking up has become increasingly recognized because it is also correlated with many other forms of dependency, including cessation of smoking [41] and tolerance [43]. The Fagerström nicotine dependence score was useful, but we needed some modification to estimate the smoking amount for EC users. Because we conducted this study with a cross-sectional design, we cannot generalize our study results to the Korean population; however, our study provides valuable information on smoking-related biomarker levels of EC and HNBC users compared to TC users. The authors believe that stakeholders can refer to our study results for comparison purposes if needed.

5. Conclusions

The nicotine dependence level among users of TC, EC, and HNBC was not significantly different. However, a positive dose–response relationship between urinary cotinine levels and daily smoking amount was found among TC or HNBC users. The time to smoking the first cigarette, one of key Fagerström nicotine addiction index questions, was significantly associated with the daily smoking amount.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/ijerph18094777/s1, Table S1: Demographic and socioeconomic status used for evaluation of the association of urinary cotinine with smoking amount adjusted for nicotine addiction levels. Table S2: Associations of biomarker concentration levels with smoking amount adjusted for nicotine addiction levels among single-type cigarette users (TC, EC, or HNB).

Author Contributions: Conceptualization, S.K. (Sungroul Kim); methodology, S.K. (Sungroul Kim), C.L. and J.L.; software, S.K. (Sungroul Kim); validation, S.K. (Sungroul Kim), and G.R.; formal analysis, S.K. (Sungroul Kim); resources, Y.K.; data curation, Y.K.; writing—original draft preparation, G.R. and S.K. (Seunghyun Kim); writing—review and editing, J.L. and S.K. (Sungroul Kim); visualization, S.K. (Sungroul Kim); supervision, S.K. (Sungroul Kim); project administration, J.L. and S.K. (Sungroul Kim); funding acquisition, S.K. (Sungroul Kim). All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by a fund (2018-E6705-00) of Research of Korea Centers for Disease Control and Prevention.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the research ethics committee of Soonchunhyang University (IRB No. 2018-BR-046-03).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Centers for Disease Control and Prevention (CDC). What Are the Risk Factors for Lung Cancer? Available online: https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm (accessed on 22 December 2019).
2. Tolstrup, J.S.; Hvidtfeldt, U.A.; Flachs, E.M.; Spiegelman, D.; Heitmann, B.L.; Bälter, K.; Goldbourt, U.; Hallmans, G.; Knekt, P.; Liu, S.; et al. Smoking and risk of coronary heart disease in younger, middle-aged, and older adults. *Am. J. Public Health* 2014, 104, 96–102. [CrossRef] [PubMed]
3. CDC (Centers for Disease Control and Prevention). Health Effects of Cigarette Smoking. 2020. Available online: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking/index.htm (accessed on 21 February 2021).
4. World Health Organization. WHO Report on the Global Tobacco Epidemic. 2019. Available online: https://www.who.int/tobacco/surveillance/policy/country_profile/kor.pdf?ua=1 (accessed on 17 March 2021).
5. World Health Organization (WHO). Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS). In Proceedings of the Conference of the Parties to the WHO Framework Convention on Tobacco Control, Delhi, India, 7–12 November 2016.
6. Fairchild, A.L.; Lee, J.S.; Bayer, R.; Curran, J. E-Cigarettes and the Harm-Reduction Continuum. *N. Engl. J. Med.* 2018, 378, 216–219. [CrossRef] [PubMed]
7. Kang, H.; Cho, S-I. Heated tobacco product use among Korean adolescents. *Tob. Control.* 2019, 29, 466–468. [CrossRef] [PubMed]
8. Lee, C.; Kim, S.; Cheong, Y. Issues of new types of tobacco (e-cigarette and heat-not-burn tobacco): From the perspective of ‘tobacco harm reduction’. *J. Korean Med. Assoc.* 2018, 61, 181. [CrossRef]
9. Lee, J.; Lee, S. Korean-made heated tobacco product, ‘lil’. *Tob. Control.* 2018, 28, e156–e157. [CrossRef] [PubMed]
10. Kim, T.-I. Heat-not-burn cigarettes heat up controversy. *J. Periodontal Implant Sci.* 2018, 48, 201. [CrossRef] [PubMed]
11. Korea National Health and Nutrition Survey (KNHANES). *Korea National Health and Nutrition Survey KNHANES: Smoker Panel 3rd Follow-Up*; Korea National Health and Nutrition Survey (KNHANES): Seoul, Korea, 2018.
12. World Health Organization (WHO). Tobacco Free Initiative (TFI): Heat-Not-Burn Tobacco Products Information Sheet. 2020. Available online: https://apps.who.int/tobacco/publications/prod_regulation/heat-not-burn-products-information-sheet/en/index.html (accessed on 16 January 2021).
13. Stolerman, I.P.; Jarvis, M.J. The scientific case that nicotine is addictive. *Psychopharmacology* 1995, 117, 2–10. [CrossRef]
14. Shiffman, S.; Ferguson, S.G.; Dunbar, M.S.; Scholl, S.M. Tobacco Dependence Among Intermittent Smokers. *Nicotine Tob. Res.* 2012, 14, 1372–1381. [CrossRef] [PubMed]
15. Tindle, H.A.; Shiffman, S. Smoking Cessation Behavior Among Intermittent Smokers Versus Daily Smokers. *Am. J. Public Health* 2011, 101, e1–e3. [CrossRef] [PubMed]
16. Luoto, R.; Utela, A.; Puska, P. Occasional smoking increases total and cardiovascular mortality among men. *Nicotine Tob. Res.* 2000, 2, 133–139. [CrossRef] [PubMed]
17. Benowitz, N.L. Nicotine addiction. *N. Engl. J. Med.* 2010, 362, 2295–2303. [CrossRef] [PubMed]
18. World Health Organization. *Electronic Nicotine Delivery Systems: Report by WHO*; WHO: Geneva, Switzerland, 2004.
19. Bullen, C.; Howe, C.; Laugesen, M.; McRobbie, H.; Parag, V.; Williman, J.; Walker, N. Electronic cigarettes for smoking cessation: A randomised controlled trial. *Lancet* 2013, 382, 1629–1637. [CrossRef]
20. Hartmann-Boyce, J.; McRobbie, H.; Bullen, C.; Begg, R.; Stead, L.F.; Hajek, P. Electronic cigarettes for smoking cessation. *Cochrane Database Syst. Rev.* 2013. [CrossRef]
21. De Meneses-Gaya, I.C.; Zuardi, A.W.; Loureiro, S.R.; Crippa, J.A.D.S. Psychometric properties of the Fagerström Test for Nicotine Dependence. *J. Bras. Pneumol.* 2009, 35, 73–82. [CrossRef] [PubMed]
22. Hudmon, K.S.; Marks, J.L.; Pomerleau, C.S.; Bolt, D.M.; Brigham, J.; Swan, G.E. A multidimensional model for characterizing tobacco dependence. *Nicotine Tob. Res.* 2003, 5, 655–664. [CrossRef] [PubMed]
23. Moolchan, E.T.; Radzius, A.; Epstein, D.H.; Uhl, G.; Gorelick, D.A.; Cadet, J.L.; Henningfield, J.E. The Fagerstrom Test for Nicotine Dependence and the Diagnostic Interview Schedule: Do they diagnose the same smokers? *Addict. Behav.* 2002, 27, 101–113. [CrossRef]
24. Fagerstrom, K.-O.; Schneider, N.G. Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire. *J. Behav. Med.* 1989, 12, 159–182. [CrossRef]
25. Heatherton, T.F.; Kozlowski, L.T.; Frecker, R.C.; Fagerstrom, K.-O. The Fagerstrom Test for Nicotine Dependence: A revi-sion of the Fagerstrom Tolerance Questionnaire. *Br. J. Psychol.* 1991, 86, 1119–1127. [CrossRef]
26. Gregg, E.; Fisher, A.-L.; Lowe, F.; McEwan, M.; Massey, E. An approach to the validation of biomarkers of harm for use in a tobacco context. *Regul. Toxicol. Pharmacol.* 2006, 44, 262–267. [CrossRef]
27. Hatsukami, D.K.; Hecht, S.S.; Hennrikus, D.J.; Joseph, A.M.; Pentel, P.R. Biomarkers of tobacco exposure or harm: Applica-tion to clinical and epidemiological studies. 25–26 October 2001, Minneapolis, Minnesota. *Nicotine Tob. Res.* 2003, 5, 387–396. [PubMed]
28. Institute of Medicine. *Scientific Standards for Studies on Modified Risk Tobacco Products;* The National Academies Press: Washington, DC, USA, 2012; p. 370.
29. Chang, C.M.; Edwards, S.H.; Arab, A.; Del Valle-Pinero, A.Y.; Yang, L.; Hatsukami, D.K. Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop. *Cancer Epidemiol. Biomark. Prev.* 2017, 26, 291–302. [CrossRef]
30. Schick, S.F.; Blount, B.C.; Jacob, P.; Saliba, N.A.; Bernert, J.T.; Hellani, A.E.; Jatlow, P.; Pappas, R.S.; Wang, L.; Fouleds, J.; et al. Biomarkers of exposure to new and emerging tobacco delivery products. *Ann. J. Physiol. Lung Cell. Moll. Physiol.* 2017, 313, L425–L452. [CrossRef] [PubMed]

31. Newton, D.F. University of Toronto Peripheral Biomarkers of Tobacco-Use Disorder: A Systematic Review. *Addict. Addict. Disord.* 2019, 6, 1–11. [CrossRef]

32. National Institutes of Health (NIH); National Institute on Drug Abuse (NIDA); The U.S. Food and Drug Administration (FDA). The Population Assessment of Tobacco and Health (PATH) Study. Available online: https://www.drugabuse.gov/research/nida-research-program-activities/population-assessment-tobacco-health-path-study (accessed on 13 January 2021).

33. International Tobacco Control (ITC). International Tobacco Control Policy Evaluation Project. Available online: https://itcproject.s3.amazonaws.com/uploads/documents/ITC_KRA1_Recruitment_web_Eng_Kor_15Oct2020.pdf (accessed on 22 February 2021).

34. Goniewicz, M.L.; Smith, D.M.; Edwards, K.C.; Blount, B.C.; Caldwell, K.L.; Feng, J.; Wang, L.; Christensen, C.; Ambrose, B.; Borek, N.; et al. Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. *JAMA Netw. Open* 2018, 1, e185937. [CrossRef] [PubMed]

35. McGuffey, J.E.; Wei, B.; Bernert, J.T.; Morrow, J.C.; Xia, B.; Wang, L.; Blount, B.C. Validation of a LC-MS/MS Method for Quantifying Urinary Nicotine, Six Nicotine Metabolites and the Minor Tobacco Alkaloids—Anatabine and Anabasine—in Smokers’ Urine. *PLoS ONE* 2014, 9, e101816. [CrossRef] [PubMed]

36. Wang, L.; Bernert, J.T.; Benowitz, N.L.; Feng, J.; Jacob, P., 3rd; McGahee, E.; Caudill, S.P.; Scherer, G.; Scherer, M.; Pylum, N.; et al. Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine. *Cancer Epidemiol. Biomark. Prev.* 2018, 27, 1083–1090. [CrossRef] [PubMed]

37. ISO (International Organization for Standardization). *Routine Analytical Cigarette-Smoking Machine—Definitions and Standard Conditions*; ISO: Geneva, Switzerland, 2012.

38. Oliveri, D.; Liang, Q.; Sarkar, M. Real-World Evidence of Differences in Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers. *Nicotine Tob. Res.* 2019, 22, 1114–1122. [CrossRef]

39. Muscat, J.E.; Stellman, S.D.; Caraballo, R.S.; Richie, J.P. Time to First Cigarette after Waking Predicts Cotinine Levels. *Cancer Epidemiol. Biomark. Prev.* 2009, 18, 3415–3420. [CrossRef]

40. Gu, F.; Wacholder, S.; Kovalchik, S.; Panagiotou, O.A.; Reyes-Guzman, C.; Freedman, N.D.; De Matteis, S.; Conson-ni, D.; Bertazzi, P.A.; Bergen, A.W.; et al. Time to Smoke First Morning Cigarette and Lung Cancer in a Case–Control Study. *J. Natl. Cancer Inst.* 2014, 106, dju118. [CrossRef]

41. Baker, T.B.; Piper, M.E.; McCarthy, D.E.; Bolt, D.M.; Smith, S.S.; Kim, S.Y.; Colby, S.; Conti, D.; Giovino, G.A.; Hatsukami, D.; et al. Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. *Nicotine Tob. Res.* 2007, 9 (Suppl. 4), S555–S570. [PubMed]

42. Mamoun, M.; Bergen, A.W.; Shihe, J.; Wiggins, A.; Brody, A.L. Biomarkers of Response to Smoking Cessation Pharma-therapies: Progress to Date. *CNS Drugs* 2015, 29, 359–369. [CrossRef] [PubMed]

43. Pillitteri, J.L.; Kozlowski, L.T.; Sweeney, C.T.; Heatherton, T.F. Individual differences in the subjective effects of the first cigarette of the day: A self-report method for studying tolerance. *Exp. Clin. Psychopharmacol.* 1997, 5, 83–90. [CrossRef] [PubMed]